6 Based on these findings, recognizing diastolic dysfunction in boys with DMD may allow patients at risk of earlier cardiomyopathic progression to be identified sooner. Findings from a recent ...

Muscular dystrophy is a disease caused by a genetic mutation. The muscles of muscular dystrophy patients weaken.. | Genetics ...

Further research is needed to determine how once-weekly viltolarsen can slow disease progression and preserve motor function in boys and young men with Duchenne muscular dystrophy (DMD).

The results provided no evidence that ezutromid is having a meaningful effect on slowing DMD progression.” Summit will now redirect its resources to focus on antibiotic pipeline starting phase 3 ...

The trial was able to elicit more than double the microdystrophin gene in patients after 90 days of treatment.

There is an unmet need for therapies targeting Duchenne muscular dystrophy (DMD)–related heart disease, and phase 2 results suggest ifetroban may improve left ventricular ejection fraction in patients ...

"The company also plans to collaborate with academic institutions to collect additional natural history and magnetic resonance imaging data on DMD progression during 2015," according to Sanyal ...

Solid Biosciences’ gene therapy uses a shortened version of the dystrophin protein, which is engineered to mimic the key functions of full-length dystrophin and allows it be delivered more effectively ...

Results show improved functional outcomes for people with Duchenne muscular dystrophy who are ambulatory. Elevidys, which is ...

Diastolic Dysfunction May Predict Rapid Cardiomyopathy Progression in Duchenne Muscular Dystrophy Previous echocardiography studies have suggested that diastolic dysfunction may precede systolic ...